Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Trial at the UKE: Vaccine reliably activates the immune system response against Ebola

02.04.2015

The initial results of a clinical Phase I trial of a potential vaccine against the dreaded Ebola virus are now available at the Hamburg-Eppendorf University Medical Center (UKE). As this trial was being conducted, scientists in Geneva (Switzerland), Lambaréne (Gabon), and Kilifi (Kenya) were also testing the “rVSV-ZEBOV” vaccine on a total of 158 healthy adult volunteers. The initial results were published today in the New England Journal of Medicine (NEJM).

“We are delighted that the UKE supports the global fight against Ebola in this way, together with other scientists and experts from the German Center for Infection Research (DZIF). A vaccine is still urgently needed, since the current Ebola epidemic has not yet been defeated and the possibility of future outbreaks cannot be ruled out,” said Prof. Dr. Burkhard Göke, Medical Director and Chief Executive Officer of the UKE.

“We have been successful in initiating this important vaccine trial so quickly and carrying it out successfully together with the other centers despite significant regulatory, logistical, and organizational hurdles,” says Prof. Dr. Ansgar W. Lohse, Director of the First Department of Internal Medicine. “Never has a vaccine been developed as quickly as in the case of Ebola.”

Phase I of the clinical trial for the vaccine candidate termed “rVSV-ZEBOV” has been ongoing in the Clinical Trial Center North (CTC North) at the UKE since November 2014. “The preliminary results for tolerability, safety, and the immune response to the vaccine candidate are promising,” explains Prof. Dr. Marylyn Addo.

“The adverse reactions were generally mild or moderate and within the limits of what can be expected when using live vaccines.” The specialist for infectious diseases headed the trial at the UKE in Hamburg and is one of the authors of the recent publication outlining the results for all four sites. The scientists involved are participants in VEBCON, a consortium of experts founded by the WHO, the goal of which is rapid and coordinated clinical testing of the Ebola vaccine in Africa.

About the trial
A total of 158 healthy volunteers at the four locations were vaccinated with increasing doses of the potential vaccine. A double-blind study was conducted in Geneva. The rVSV-ZEBOV vaccine used is an attenuated, genetically modified strain of vesicular stomatitis virus (VSV), which bears a surface protein of the Ebola virus. The goal is to help the vaccinated person's immune system produce antibodies to prevent an outbreak of the disease upon contact with the Ebola virus. For the first time, scientists have tested the vaccine's safety and tolerability in people, as well as the human immune response to it.
In the Clinical Trial Center North at the UKE, volunteer subjects received the potential vaccine. They then remained under observation in the hospital for three to five days, after which they were closely monitored as outpatients. Prof. Addo: “The commitment of the subjects was immense; many volunteered well before the start of the trial. This greatly facilitated our work and contributed to the trial's success.”

Important results
Safety and tolerability: No serious adverse reactions associated with the vaccine have been observed. Since it is a live vaccine, small amounts of the vaccine virus were found in the blood, as expected, but only in the first few days. Virus replication appears to be controlled and limited by the immune system. No viruses were detected in saliva and urine.

Effect on the immune system: The vaccine stimulated the immune system of all participants to produce antibodies specifically targeting the Ebola surface protein. The antibodies were able to inhibit infection by the Ebola virus in vitro. “These results show that the new vaccine has the potential to be used even during dramatic outbreaks such as the current Ebola virus outbreak,” says Prof. Dr. Stephan Becker, whose laboratory at the Philipp University of Marburg evaluated the immune responses of all trial participants.

The initial results will now be utilized in further trials in West Africa that will use the optimal doses previously determined. In Guinea, where the Ebola epidemic still claims many lives, the vaccine is already being tested in a larger Phase II/III trial based on the initial results of the vaccine trial described and people in contact with Ebola patients are being vaccinated. About 10,000 people are expected to participate in these trials in the coming weeks.

Collaboration
The German Center for Infection Research (DZIF) supported the preparation of the trial at the UKE in Hamburg. DZIF, the Federal Ministry of Health (BMG), and the British Wellcome Trust provided the funding to prepare and implement the clinical trial. The Canadian Health Authority donated the vaccine candidate to the WHO, which then made it available for these trials. All parties involved are thus responding quickly and jointly to the dramatic Ebola epidemic in West Africa. In preparing the trial, the DZIF scientists in Hamburg, Gießen-Marburg-Langen, and Tübingen worked closely with the Paul Ehrlich Institute (PEI), which, as a partner of the DZIF, supports research into new vaccine platforms. In Hamburg, the trial was conducted in close collaboration with the Heinrich Pette Institute and the Bernhard Nocht Institute.

Commitment of the UKE to the fight against Ebola
In August 2014, a WHO employee infected with the Ebola virus was admitted to the UKE. After five weeks in special isolation, he was discharged as cured in early October 2014. The attending physicians and infectious disease specialists at the UKE, the Bernhard Nocht Institute for Tropical Medicine (BNITM), and the German Center for Infection Research (DZIF) reported that the patient had to contend with serious complications. In addition to severe dehydration as a result of the Ebola infection, bacterial sepsis required further intensive care measures.

Literature:
Selidji T. Agnandji, M.D.; Angela Huttner, M.D.; Madeleine E. Zinser M.D.; Patricia Njuguna M. M.D. et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe — Preliminary Report. N Engl J Med, online first release on April 1, 2015. DOI: 10.1056/NEJMoa1411627

Christine Trowitzsch | idw - Informationsdienst Wissenschaft
Further information:
http://www.uke.uni-hamburg.de

More articles from Health and Medicine:

nachricht TSRI researchers develop new method to 'fingerprint' HIV
29.03.2017 | Scripps Research Institute

nachricht Periodic ventilation keeps more pollen out than tilted-open windows
29.03.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Researchers shoot for success with simulations of laser pulse-material interactions

29.03.2017 | Materials Sciences

Igniting a solar flare in the corona with lower-atmosphere kindling

29.03.2017 | Physics and Astronomy

As sea level rises, much of Honolulu and Waikiki vulnerable to groundwater inundation

29.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>